UroGen Pharma Ltd (URGN)
13.22
+0.01
(+0.08%)
USD |
NASDAQ |
May 17, 16:00
13.22
0.00 (0.00%)
After-Hours: 20:00
UroGen Pharma Revenue (Quarterly): 18.78M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 18.78M |
| December 31, 2023 | 23.53M |
| September 30, 2023 | 20.85M |
| June 30, 2023 | 21.14M |
| March 31, 2023 | 17.19M |
| December 31, 2022 | 18.09M |
| September 30, 2022 | 16.10M |
| June 30, 2022 | 16.60M |
| March 31, 2022 | 13.56M |
| December 31, 2021 | 16.17M |
| September 30, 2021 | 11.35M |
| June 30, 2021 | 13.03M |
| March 31, 2021 | 7.485M |
| December 31, 2020 | 7.966M |
| September 30, 2020 | 3.461M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.372M |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 0.018M |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | 0.283M |
| June 30, 2018 | 0.364M |
| March 31, 2018 | 0.481M |
| December 31, 2017 | 0.327M |
| September 30, 2017 | 7.812M |
| June 30, 2017 | |
| March 31, 2017 | 0.019M |
| December 31, 2016 | 17.53M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.018M
Minimum
Jun 2019
23.53M
Maximum
Dec 2023
13.28M
Average
16.10M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Agenus Inc | 28.00M |
| Exelixis Inc | 425.23M |
| Geron Corp | 0.304M |
| Protalix BioTherapeutics Inc | 3.748M |
| InfuSystems Holdings Inc | 32.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.29M |
| Total Expenses (Quarterly) | 44.52M |
| EPS Diluted (Quarterly) | -0.97 |
| Enterprise Value | 411.18M |
| Gross Profit Margin (Quarterly) | 90.80% |
| Profit Margin (Quarterly) | -171.9% |
| Earnings Yield | -25.26% |
| Normalized Earnings Yield | -20.94 |